Literature DB >> 26475674

High-level expression and preparation of recombinant human fibrinogen as biopharmaceuticals.

Masaki Hirashima1, Takayuki Imamura1, Kentaro Yano2, Ryoichi Kawamura1, Akihiro Meta1, Yoshiyuki Tokieda2, Toshihiro Nakashima3.   

Abstract

Fibrinogen is a large and complex glycoprotein containing two sets of each of three different chains (α, β and γ). There have been no reports of high-level expression of fibrinogen at commercial levels using mammalian cultured cells such as CHO cells because of the difficulty in highly expressing a protein with such a complex structure. We achieved high-level (1.3 g/l or higher) expression of recombinant human fibrinogen using CHO DG44 cells by optimizing the expression system and culture conditions. We also succeeded in establishing a high-recovery preparation method for recombinant fibrinogen that rarely yields degraded products. To characterize the properties of the recombinant human fibrinogen, we performed SDS-PAGE; western blotting of the α, β and γ chains using specific antibodies and scanning electron microscopy observations of fibrin fibres. We also evaluated the functional equivalence between recombinant fibrinogen and plasma fibrinogen with respect to the release of fibrinopeptides initiated by thrombin and its cross-linking properties. The basic properties of recombinant fibrinogen showed no apparent differences from those of plasma fibrinogen. Here, we report the development of methods for the culture and preparation of recombinant human fibrinogen of satisfactory quality that can be scaled up to the commercial level.
© The Authors 2015. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.

Entities:  

Keywords:  CHO DG44; biopharmaceuticals; high-level expression; high-recovery preparation; recombinant human fibrinogen

Mesh:

Substances:

Year:  2015        PMID: 26475674      PMCID: PMC4892781          DOI: 10.1093/jb/mvv099

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  28 in total

Review 1.  The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review.

Authors:  L J Currie; J R Sharpe; R Martin
Journal:  Plast Reconstr Surg       Date:  2001-11       Impact factor: 4.730

2.  Preparation of recombinant alpha-thrombin: high-level expression of recombinant human prethrombin-2 and its activation by recombinant ecarin.

Authors:  Hiroshi Yonemura; Takayuki Imamura; Kenji Soejima; Yo Nakahara; Wataru Morikawa; Yoshitaka Ushio; Yasuharu Kamachi; Hiroshi Nakatake; Keishin Sugawara; Tomohiro Nakagaki; Chikateru Nozaki
Journal:  J Biochem       Date:  2004-05       Impact factor: 3.387

3.  Comparable effect of recombinant and plasma-derived human fibrinogen concentrate on ex vivo clot formation after cardiac surgery.

Authors:  V Radulovic; F Baghaei; I Fagerberg Blixter; S Samuelsson; A Jeppsson
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

Review 4.  Optimal and consistent protein glycosylation in mammalian cell culture.

Authors:  Patrick Hossler; Sarwat F Khattak; Zheng Jian Li
Journal:  Glycobiology       Date:  2009-06-03       Impact factor: 4.313

5.  The conversion of fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen.

Authors:  O V Gorkun; Y I Veklich; J W Weisel; S T Lord
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

6.  Electrospray ionisation analysis of human fibrinogen.

Authors:  S O Brennan
Journal:  Thromb Haemost       Date:  1997-09       Impact factor: 5.249

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  High-level expression of recombinant human fibrinogen in the milk of transgenic mice.

Authors:  D Prunkard; I Cottingham; I Garner; S Bruce; M Dalrymple; G Lasser; P Bishop; D Foster
Journal:  Nat Biotechnol       Date:  1996-07       Impact factor: 54.908

Review 9.  Molecular farming of pharmaceutical proteins.

Authors:  R Fischer; N Emans
Journal:  Transgenic Res       Date:  2000       Impact factor: 3.145

10.  The conversion of fibrinogen to fibrin. XIII. Dissolution of fibrin and inhibition of clotting by various neutral salts.

Authors:  S SHULMAN; S KATZ; J D FERRY
Journal:  J Gen Physiol       Date:  1953-07       Impact factor: 4.086

View more
  2 in total

1.  Development of Transient Recombinant Expression and Affinity Chromatography Systems for Human Fibrinogen.

Authors:  Grega Popovic; Nicholas C Kirby; Taylor C Dement; Kristine M Peterson; Caroline E Daub; Heather A Belcher; Martin Guthold; Adam R Offenbacher; Nathan E Hudson
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 6.208

2.  Engineering CRISPR/Cas9 for Multiplexed Recombinant Coagulation Factor Production.

Authors:  Colby J Feser; Christopher J Lees; Daniel T Lammers; Megan J Riddle; Jason R Bingham; Matthew J Eckert; Jakub Tolar; Mark J Osborn
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.